Dalrada Financial Corporation Appoints Professor Elizabeth Winzeler to Healthcare Advisory Board

SAN DIEGO--(BUSINESS WIRE)-- Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada Financial Corporation”, “Dalrada”) today announced the appointment of Elizabeth Ann Winzeler, Ph.D., a Professor in the Department of Pediatrics at the University of California, San Diego, School of Medicine, as a member of the Dalrada Health advisory board. The group is composed of distinguished life sciences industry leaders whose industry knowledge and guidance are intended to accelerate Dalrada Health’s national healthcare model.

Dalrada envisions a comprehensive healthcare solution with unique offerings that include physicians and clinicians at treatment clinics, and eventually expanding into telemedicine, engaging Dalrada-owned testing facilities and laboratories, and utilizing Company-specific technologies to facilitate rapid growth of the business. The Company plans on entering the pharmaceutical space with an accelerated strategic plan to leverage its pre-existing capabilities.

Brian Bonar, Dalrada’s Chairman and CEO, states, “Dr. Winzeler’s vast experience in academic and industrial antimicrobial drug discovery will have a positive impact on accelerating Dalrada Health’s initiatives in the pharmaceutical market.”

Dr. Winzeler received a Ph.D. from the Department of Developmental Biology at Stanford University, where she trained under microbiologists and geneticists, before a joint position at the Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation. Her efforts with malaria drug discovery yielded several novel antimalarial chemotypes that are currently in late-stage clinical trials.

At UCSD, Dr. Winzeler leads a group that uses systematic, data-intensive methods to solve problems at the interface of host-pathogen biology, typically involving large collections of chemical screening data and whole-genome sequencing.

Dr. Winzeler has received many accolades throughout her career, including awards from the Keck Foundation, the Ellison Medical Foundation, and the Bill and Melinda Gates Foundation, where she is currently the Director of the Foundation’s Malaria Drug Accelerator (MalDA). In 2014, Dr. Winzeler was awarded the Bailey-Ashford Medal for distinguished achievements in tropical medicine. Also a fellow of the American Academy of Microbiology, Dr. Winzeler was elected to the National Academy of Medicine this year.

Dalrada Financial Corporation and its subsidiaries provide value by making timely and impactful products and services available within health, technology, and clean energy markets. To learn more about how Dalrada continuously creates innovative solutions to address the complex challenges of today and the future, please visit www.Dalrada.com.

About Dalrada:

Dalrada Financial Corporation drives innovation that positively impacts people, businesses, and the planet. With subsidiaries that are firmly positioned in the world’s top three-growing industries of healthcare, clean energy, and technology, Dalrada creates solutions that are sustainable, affordable, and accessible.

The company works continually to produce disruptive products and services that accelerate positive change for current and future generations. Dalrada’s global solutions directly address climate change, post-pandemic gaps in the healthcare industry, and technology solutions for a new era of human behavior and interaction, ensuring a bright future for the world around us.

Established in 1982, Dalrada has since grown its footprint to include the unique business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies. Please visit www.dalrada.com and follow us on Twitter, Facebook, and LinkedIn for more information.

Disclaimer:

Statements in this press release are not historical facts, the statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations regarding these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the US Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005028/en/